PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[midastouch017]

If I get a response will update here.

I assume no PLX reply?



Herewith another company in a similar situation:

Revance price target lowered to $30 from $32 at Mizuho Mizuho analyst Vamil Divan lowered the firm's price target on Revance to $30 from $32 and keeps a Buy rating on the shares following the company's Q3 results. Revance provided a business update with the focus being on the company's comments that suggest FDA approval of its botulinum toxin Daxi may be delayed due to an inability of the FDA to travel and inspect the company's manufacturing facility, Divan tells investors in a research note. Given the FDA Action Date is November 25, the analyst now assumes the product will not be approved on time. He assumes a first half of 2021 approval and launch.